Abstract
In recent years, morbidity and mortality of prostate cancer in China have increased rapidly, and it has become a common malignant tumor among the top 5 male tumors in some areas. Multidisciplinary comprehensive treatment is the key to improve the survival rate and quality of life of prostate cancer. However, the drugs used to construct multidisciplinary comprehensive treatment were based on anatomy, treatment stage and clinical trials, which lacked individualized treatment for complex tumor scenarios. With the rapid development of precision medicine, molecular imaging, molecular typing and pharmacogenomics will be added to these three elements, which will help to improve the individualized level of multidisciplinary comprehensive treatment. This kind of precise multidisciplinary comprehensive treatment urgently needs the vigorous promotion of ideas, researchers and researches.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Zhonghua wai ke za zhi [Chinese journal of surgery]
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.